Abstract
The article informs about knowledge and experiences with long acting injection antipsychotics (LAI-A). Authors estimate that prescriptions of LAI-A in the Czech Republic represent 6% of all antipsychotics.
There are estimations that 10% of patients with schizophrenia use LAI-A in Finland and about 25-33 % in Great Britain. We hypothesize that increased prescription of LAI-A could lead to decreased relapse rate and rehospitalisation what some studies indicate.
Further, authors try to define who is ideal patient for the use of the most new LAI-A. The olanzapine pamoat might be ideal for patiens with previous response to oral olanzapine or other MARTA antipsychotics and for non-adherent patients sensitive to extrapyramidal and prolactin side effects.
The target group of paliperidone palmitate might be specified by previous response to SDA antipsychotics as well as sensitivity to sedation, weight gain and anticholinergic side effects